[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557990":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":41,"collaborators":20,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":20,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":20,"overallStatus":29,"whyStopped":20,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Leiden University Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Microsampling arm","EXPERIMENTAL","Patients who use an oral oncolytic will be asked to provide twelve microsamples obtained by finger prick:\n\n* 6 dried blood spots (DBS)\n* 6 volumetric absorptive microsampling (VAMS))",[13],"Diagnostic Test: Therapeutic drug monitoring with a dried blood spot and microatainer.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Therapeutic drug monitoring with a dried blood spot and microatainer.","Patients who use an oral oncolytic will be asked to provide four paired whole blood (WB) samples obtained by venapuncture.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Tom Van Der Hulle, MD PhD","CONTACT","0031715263464","t.van_der_hulle@lumc.nl",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":20},"RECRUITING","Leiden","South Holland","2333ZA","Netherlands","NL",{"type":36,"coordinates":37},"Point",[38,39],4.49306,52.15833,{"lat":39,"lon":38},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","dr. Tom van der Hulle","Medical Oncologist","100557990","microsampling-for-therapeutic-drug-monitoring-of-oral-oncolytics-in-oncology-patients-100557990",false,"NCT06545292","Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients","Microsampling to Facilitate Drug Monitoring of Oncolytics","MSTDM","Inclusion Criteria:\n\n* Willing and able to provide informed consent;\n* 18 years of age or older;\n* Using one or more of the following drugs: Cabozantinib, Pazopanib, Sunitinib, Lenvatinib, Imatinib, Abiraterone, Enzalutamide, Nivolumab, Ipilimumab, Pembrolizumab, Atezolizumab, Bevacizumab or Enfortumab vedotin\n\nExclusion Criteria:\n\n* Not able to sample themselves using a finger prick","ALL","18 Years","90 Years",{"count":57,"type":58},360,"ESTIMATED","INTERVENTIONAL",[61],"NA","The aim of the study is to perform a clinical validation of the analytical method for dried blood spot microsampling of cabozantinib, pazopanib, sunitinib, lenvatinib, imatinib, abiraterone, enzalutamide, nivolumab, ipilimumab, pembrolizumab, atezolizumab, bevacizumab or enfortumab vedotin. The secondary objective is to test the feasibility of home monitoring (microsampling TDM) of cabozantinib, pazopanib, sunitinib, lenvatinib, imatinib, abiraterone, enzalutamide, nivolumab, ipilimumab, pembrolizumab, atezolizumab, bevacizumab or enfortumab vedotin in oncology patients.",[64],"Drug Monitoring","2025-11-18",{"date":67,"type":68},"2025-11-21","ACTUAL",{"date":70,"type":68},"2025-10-06",{"date":72,"type":58},"2028-07-01",{"name":5,"class":6},1]